MYO3B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20762768	1.00	1/20
SCHEMBL22026540	1.00	1/20
SCHEMBL22026543	1.00	1/20
SCHEMBL29779922	1.00	1/20
SCHEMBL20762903	0.92	1/20
SCHEMBL20762935	0.91	1/20
SCHEMBL20762724	0.90	1/20
SCHEMBL20762737	0.89	1/20
SCHEMBL22065430	0.89	1/20
SCHEMBL22026524	0.89	1/20
SCHEMBL29779920	0.89	1/20
SCHEMBL29779926	0.89	1/20
SCHEMBL20763374	0.88	1/20
SCHEMBL20762799	0.86	1/20
SCHEMBL20762902	0.86	1/20
SCHEMBL20763141	0.86	1/20
SCHEMBL20763482	0.86	1/20
SCHEMBL22026542	0.86	1/20
SCHEMBL22026544	0.86	1/20
SCHEMBL22066361	0.86	1/20

Clinical trials — most relevant to MYO3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill	nan	UNKNOWN
Genetic Testing in Primary Congenital Glaucoma Patients	nan	UNKNOWN
Natural History Study for Patients With Nemaline Myopathy in Belgium	nan	NOT_YET_RECRUITING
Pediatric Evaluation and Registry for Liver Cholestasis in Canada	nan	RECRUITING
Characteristics of Nondystrophic Myotonias	nan	COMPLETED
Molecular and Genetic Studies of Congenital Myopathies	nan	RECRUITING
Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies	nan	RECRUITING
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium	nan	COMPLETED
Congenital Muscle Disease Study of Patient and Family Reported Medical Information	nan	RECRUITING
Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia	nan	COMPLETED
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment	nan	COMPLETED
Role of Ultrasound in Diagnosis of Muscle Diseases	nan	COMPLETED
Myotubular and Centronuclear Myopathy Patient Registry	nan	RECRUITING
Cardiac Arrhythmias and Sudden Death in Patients Affected With Laminopathies	nan	UNKNOWN
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD	nan	ENROLLING_BY_INVITATION
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
MYO-SHARE: MYO-MRI in Neuromuscular Diseases	nan	ENROLLING_BY_INVITATION
Clinical Importance of Carrier Status of Recessive Gene Mutations in Myopathy (CICS)	nan	UNKNOWN
B3 for NMD: Bench to Bedside and Back	nan	ENROLLING_BY_INVITATION
Chronic Muscle Disuse in the Elderly	nan	COMPLETED
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
LAMA2-related Muscular Dystrophy Brain Study	nan	WITHDRAWN
Influence of Sarcopenia on the Course of the Diseases	nan	RECRUITING
3D-Microscopic Muscle Architecture in Cerebral Palsy	nan	RECRUITING
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China	nan	ENROLLING_BY_INVITATION
Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies	nan	RECRUITING
Regulation of Muscle Protein Phenotype in Humans With Obesity	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MYO3B binder may also engage these)

Protein	Name	Similarity
Q1EG27	—	1.000	Q1EG27 →
Q8K3H5	—	0.999	Q8K3H5 →
MYO3A	Myosin-IIIa	0.994	landscape →
Q9V3Z6	—	0.993	Q9V3Z6 →
A5PF48	—	0.991	A5PF48 →
Q99MZ6	—	0.989	Q99MZ6 →
P91443	—	0.989	P91443 →
P97479	—	0.989	P97479 →
A7E2Y1	—	0.988	A7E2Y1 →
Q8N1T3	—	0.988	Q8N1T3 →
Q6GPA1	—	0.988	Q6GPA1 →
Q28970	—	0.988	Q28970 →
F8VQB6	—	0.987	F8VQB6 →
Q6PIF6	—	0.987	Q6PIF6 →
Q622K8	—	0.987	Q622K8 →
Q29P71	—	0.987	Q29P71 →
Q01989	—	0.986	Q01989 →
Q9HD67	—	0.986	Q9HD67 →
Q5SUA5	—	0.985	Q5SUA5 →
A2AQP0	—	0.985	A2AQP0 →
P79114	—	0.985	P79114 →
Q9Y2K3	—	0.984	Q9Y2K3 →
Q13402	—	0.984	Q13402 →
Q17LW0	—	0.984	Q17LW0 →
D3ZJP6	—	0.984	D3ZJP6 →
Q5ZMC2	—	0.984	Q5ZMC2 →
Q63357	—	0.981	Q63357 →
P47808	—	0.981	P47808 →
O94832	—	0.981	O94832 →
Q5SYD0	—	0.980	Q5SYD0 →